SCHEDULE: BVF Group Exits iTeos Therapeutics Stake

Biotechnology Value Fund and its affiliates have fully divested their beneficial ownership in iTeos Therapeutics, Inc., holding 0% of common stock as of June 30, 2025.

Summary

• Reporting persons, including Biotechnology Value Fund L.P. and its affiliates, filed an Amendment No. 2 to Schedule 13G regarding their holdings in iTeos Therapeutics, Inc.
• As of June 30, 2025, the reporting persons no longer beneficially owned any securities of iTeos Therapeutics, Inc.
• Their aggregate beneficial ownership of iTeos Therapeutics, Inc. common stock is now 0% of the class.
• The filing was made to report the cessation of beneficial ownership by the reporting group.

Sentiment

Score: 2

Explanation: A score of 2 reflects a strong negative sentiment due to a complete divestment by a significant institutional investor group, indicating a loss of confidence or a strategic exit from the company's stock.

Negatives

• A significant institutional investor group, Biotechnology Value Fund and its affiliates, has completely exited its position in iTeos Therapeutics, Inc.
• The divestment to 0% beneficial ownership as of June 30, 2025, signals a lack of confidence or a change in investment strategy regarding the company.

Risks

• The complete divestment by a major institutional investor may lead to negative market sentiment and increased selling pressure on iTeos Therapeutics, Inc. shares.
• This action could be interpreted by other investors as a signal of underlying concerns about the company's future prospects or valuation.

Future Outlook

NA

Industry Context

This filing reflects an investment decision by a specialized biotechnology fund. While not directly about industry trends, a fund's exit from a biotech company can sometimes reflect broader sector-specific concerns or a shift in focus within the biotech investment landscape.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential share price decline due to the complete divestment by a major institutional investor.
• Potential Investors: May view the divestment as a red flag, leading to reduced interest in investing in iTeos Therapeutics, Inc.

Key Dates

Recommendation

The complete divestment by a specialized biotechnology investment fund, Biotechnology Value Fund and its affiliates, signals a profound lack of confidence in iTeos Therapeutics, Inc.'s future prospects or current valuation. Such a significant exit by a knowledgeable institutional investor is a strong negative indicator, suggesting that the stock may face downward pressure and that the investment thesis previously held by this fund is no longer valid.

Keywords

iTeos Therapeutics, ITOS, Biotechnology Value Fund, BVF, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, biotechnology